Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.

Alberta Health services40 enrolled

Overview

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Thyroid Neoplasms

Interventions

IMRTPROCEDURE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * resected well-differentiated throid cancer with at least one high risk feature for locoregional recurrence Exclusion Criteria: * medullary or anaplastic thyroid cancer, unresectable

Outcomes

Primary Outcomes

toxicity according to RTOG criteria

locoregional control

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.